As the targeted drugs come into being in recent years, such as monoclonal antibody, great achievements have been made for the treatment of malignant lymphoma (ML). Rituximab, a monoclonal antibody against CD20 whose effective rate is up to 85% in the ifrst-line treatment of lymphoma, has become the standard ifrst-line treatment of multiple B cell lymphomas. However, how to improve the therapeutic efficacy of B lymphoma and reduce reoccurrence rate in drug-resistant patients still need to be further studied. And great importance is increasingly attached to the development of new drugs, especially tumor angiogenesis drugs, in which Bevacizumab and Endostatin are studied as the main representative for the treatment of ML. This paper mainly made a review on Current situation and prospects of anti-angiogenesis drugs for the treatment of lymphoma.